AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Jazz Pharmaceuticals to Present Phase 3 Ziihera Data in HER2+ Gastroesophageal Adenocarcinoma at ASCO GI
ByAinvest
Tuesday, Dec 2, 2025 4:06 pm ET1min read
Jazz Pharmaceuticals will present pivotal Phase 3 results of Ziihera (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium. The Phase 3 HERIZON-GEA-01 trial results demonstrate clinically meaningful improvements in progression-free survival and overall survival compared to the control arm. The company will also present a new post-hoc overall survival analysis from the HERIZON-BTC-01 Phase 2b trial in previously treated HER2+ biliary tract cancer.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet